Yes, puberty blockers are currently banned for children under eighteen in the UK. Following recommendations from the Cass Review, UK prescribers are no longer able to prescribe these medications for young people, marking a significant change in transgender healthcare provision.
Research shows that puberty blockers have been used internationally for decades to pause physical development in young people experiencing gender dysphoria. Evidence indicates that these medications can provide crucial time for young people and their families to explore their gender identity without the distress of unwanted physical changes. Many international medical organisations continue to recognise these treatments as important options in transgender healthcare.
The implementation of these restrictions has created considerable challenges for families seeking care. Guidelines from international bodies still support the careful use of puberty blockers in appropriate circumstances, whilst the UK has taken a more restrictive approach following concerns raised in the Cass Review about the evidence base and treatment pathways.
People often ask about alternatives or ways to access support during this time. Families affected by these changes may benefit from connecting with transgender support organisations and mental health services that specialise in gender identity. The situation continues to evolve, and staying informed about policy developments remains important for those navigating these challenging circumstances.